^
Association details:
| Biomarker: | TNFRSF1B overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments
Published date:
02/14/2023
Excerpt:
Importantly, high expression of TNFR2 is associated with poor responses to the treatment with ICIs in BRCA, HCC, LUSC, and MELA. In conclusion, the expression of TNFR2 in TME may be a reliable biomarker for the precision of ICIs treatment of cancer patients, and this idea merits further research.
DOI:
10.3389/fimmu.2023.1097090
